Sarah Singleton

Bio:

Ms. Singleton leads corporate communications and patient advocacy at ImmunityBio, a publicly traded, commercial-stage immunotherapy company, where she is responsible for the company’s global communications strategy, including corporate and public affairs, media relations, internal communications, and patient outreach and engagement. Since joining the company in 2019 (then NantKwest), she has developed and executed a comprehensive communications and reputation strategy supporting ImmunityBio’s growth, commercialization, pipeline, and long-term value creation.

With more than 25 years of experience, Ms. Singleton is a seasoned corporate communications and marketing executive who has held senior leadership roles across public and private companies in the biotechnology, technology, and energy sectors. She has deep expertise in corporate positioning, investor and financial communications, issues management, and integrated marketing.

Previously, Ms. Singleton served as Senior Vice President and Partner at FleishmanHillard, where she led multidisciplinary teams delivering investor relations, financial communications, and marketing programs for global clients. She holds a B.S in Journalism from the Scripps College of Communication at Ohio University.